Satya Marar
-
Research Fellow
Satya Marar is a Research Fellow at the Mercatus Center at George Mason University where he was formerly an MA Fellow. He holds an MA in Economics from George Mason University and a BA in writing and an LLB with Honors in law from Macquarie University in Sydney, Australia. He is currently pursuing an LLM in US law at George Mason University. He has previously worked at Reason Foundation and the Australian Taxpayers’ Alliance. His research interests include antitrust & competition policy, intellectual property, trade and technology policy.
Latest Work
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Re: Response to Request for Information (RFI): Commonsense Policy Options to Lower Drug Prices for Patients
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
AI Chatbots Are Helping Youths Improve Their Mental Health | DC Journal
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Comments on the Section 301 Investigation Regarding Germany’s Persistent Underpayment for Innovative Pharmaceutical Products
Submission to the United States Trade Representative (USTR), Docket Nos. USTR-2026-0463 and USTR-2026-0464 -
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The SEARCH Act Copies Europe’s Homework—and Its Mistakes | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Event Video Event Video
Right Diagnosis, Wrong Cure: Examining the True Cost of Drug Price Controls
The Mercatus Center hosted a discussion examining the true cost of drug price controls and the impacts on healthcare affordability, medicinal R&D, and innovation -
- | Antitrust and Competition Antitrust and Competition
- | Feature Feature
Right Diagnosis, Wrong Cure | Regulation
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Fixing Patent Eligibility Is an Easy Win for Innovation | The Daily Economy
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Don’t Put the Government on the Cap Table | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When rare bipartisanship threatens US tech leadership | Washington Examiner
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
When Should We Recognize Something as a Property Right? | Federalist Society Forums
-
- | Antitrust and Competition Antitrust and Competition
- | Journal Articles Journal Articles
Is Data Really a Barrier to Entry?
Rethinking Competition Regulation in Generative AI -
- | Antitrust and Competition Antitrust and Competition
- | Working Papers Working Papers
Is Data Really a Barrier to Entry? Rethinking Competition Regulation in Generative AI
Fears of data scarcity and monopolization are unfounded and risk leading to overregulation. -
- | Antitrust and Competition Antitrust and Competition
- | Research Papers Research Papers
Artificial Intelligence and Antitrust Law: A Primer
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
Unintended Consequences: The Real Effects of Populist Antitrust Policies on Competition and Small Enterprises
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
Proceedings of the 2024 Annual Mercatus Center Antitrust Forum
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
Antitrust Enforcement in 2023: Year in Review for the Federal Trade Commission and the Department of Justice
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
The Robinson-Patman Act: A Statute at Odds with Competition and Economic Welfare
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
When Should We Recognize Something as a Property Right? | Federalist Society Forums
-
- | Antitrust and Competition Antitrust and Competition
- | Radio Appearance Radio Appearance
Why Are Medicine Prices So High in America? | The Brian Nichols Show
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
Trump’s Attempt To Cure Drug Prices Is a Wrong Step in the Right Direction | Moving Forward with Young Voices
-
- | Antitrust and Competition Antitrust and Competition
- | Radio Appearance Radio Appearance
The Drug Act Could Backfire by Raising Costs for Patients and Taxpayers | The Jeff Kennedy Show
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
The Pandemic's Effect on Schools and School Choice | The Chris Spangle Show
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Re: Response to Request for Information (RFI): Commonsense Policy Options to Lower Drug Prices for Patients
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Comments on the Section 301 Investigation Regarding Germany’s Persistent Underpayment for Innovative Pharmaceutical Products
Submission to the United States Trade Representative (USTR), Docket Nos. USTR-2026-0463 and USTR-2026-0464 -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Foreign Governments’ Ex Ante DMA-Style Rules Harm Competition and Innovation in Digital Markets While Discriminating Against US Firms
Examines how DMA-style digital regulation affects competition, trade, and antitrust policy -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Consultation on the First Review of the Digital Markets Act
Posted by the European Commission Directorate-General for Competition, Directorate-General for Communications Networks, Content and Technology on July 3, 2025 -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Comments to the UK Intellectual Property Office on the Proposed Regulatory Framework for Establishing a Rate Determination Track (RDT) to Solve Rate Disputes for Standard Essential Patents (SEPs)
Why UKIPO’s plan for IPEC to set SEP royalty rates threatens innovation, IP rights, and UK competitiveness -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Omnicom Group Inc. (‘‘Omnicom’’) and the Interpublic Group of Companies, Inc. (‘‘IPG’’); Analysis of Agreement Containing Consent Order to Aid Public Comment
Comment urges FTC to clarify that the Order targets only joint, collusive behavior and not unilateral decisions by Omnicom -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
The Federal Trade Commission’s and the U.S. Department of Justice’s Request for Information on Harmful Practices and on Potential Regulation or Legislation to Protect Consumers in the Concert and Entertainment Industry
Comment urges the FTC and DOJ to target specific anticompetitive conduct and adopt consumer-focused rules instead of structural breakups -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
The European Commission's Draft "Proposal for a Regulation of the European Parliament and of the Council on Standard Essential Patents" is Unnecessary and Harmful
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
AI Chatbots Are Helping Youths Improve Their Mental Health | DC Journal
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The SEARCH Act Copies Europe’s Homework—and Its Mistakes | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Event Video Event Video
Right Diagnosis, Wrong Cure: Examining the True Cost of Drug Price Controls
The Mercatus Center hosted a discussion examining the true cost of drug price controls and the impacts on healthcare affordability, medicinal R&D, and innovation -
- | Antitrust and Competition Antitrust and Competition
- | Feature Feature
Right Diagnosis, Wrong Cure | Regulation
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Fixing Patent Eligibility Is an Easy Win for Innovation | The Daily Economy
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Don’t Put the Government on the Cap Table | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When rare bipartisanship threatens US tech leadership | Washington Examiner
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Bad Medicine: Why Breaking Up Big Health Care Could Make It Worse | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Getting The Bureaucracy Out of Broadband | The Daily Economy
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
California’s latest attack on big tech is BASED on bad economics | Los Angeles Daily News
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Re: Response to Request for Information (RFI): Commonsense Policy Options to Lower Drug Prices for Patients
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
AI Chatbots Are Helping Youths Improve Their Mental Health | DC Journal
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Comments on the Section 301 Investigation Regarding Germany’s Persistent Underpayment for Innovative Pharmaceutical Products
Submission to the United States Trade Representative (USTR), Docket Nos. USTR-2026-0463 and USTR-2026-0464 -
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The SEARCH Act Copies Europe’s Homework—and Its Mistakes | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Event Video Event Video
Right Diagnosis, Wrong Cure: Examining the True Cost of Drug Price Controls
The Mercatus Center hosted a discussion examining the true cost of drug price controls and the impacts on healthcare affordability, medicinal R&D, and innovation -
- | Antitrust and Competition Antitrust and Competition
- | Feature Feature
Right Diagnosis, Wrong Cure | Regulation
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Fixing Patent Eligibility Is an Easy Win for Innovation | The Daily Economy
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Don’t Put the Government on the Cap Table | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When rare bipartisanship threatens US tech leadership | Washington Examiner
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
When Should We Recognize Something as a Property Right? | Federalist Society Forums
-
- | Antitrust and Competition Antitrust and Competition
- | Journal Articles Journal Articles
Is Data Really a Barrier to Entry?
Rethinking Competition Regulation in Generative AI -
- | Antitrust and Competition Antitrust and Competition
- | Working Papers Working Papers
Is Data Really a Barrier to Entry? Rethinking Competition Regulation in Generative AI
Fears of data scarcity and monopolization are unfounded and risk leading to overregulation. -
- | Antitrust and Competition Antitrust and Competition
- | Research Papers Research Papers
Artificial Intelligence and Antitrust Law: A Primer
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
Unintended Consequences: The Real Effects of Populist Antitrust Policies on Competition and Small Enterprises
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
Proceedings of the 2024 Annual Mercatus Center Antitrust Forum
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
Antitrust Enforcement in 2023: Year in Review for the Federal Trade Commission and the Department of Justice
-
- | Antitrust and Competition Antitrust and Competition
- | Policy Briefs Policy Briefs
The Robinson-Patman Act: A Statute at Odds with Competition and Economic Welfare
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
When Should We Recognize Something as a Property Right? | Federalist Society Forums
-
- | Antitrust and Competition Antitrust and Competition
- | Radio Appearance Radio Appearance
Why Are Medicine Prices So High in America? | The Brian Nichols Show
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
Trump’s Attempt To Cure Drug Prices Is a Wrong Step in the Right Direction | Moving Forward with Young Voices
-
- | Antitrust and Competition Antitrust and Competition
- | Radio Appearance Radio Appearance
The Drug Act Could Backfire by Raising Costs for Patients and Taxpayers | The Jeff Kennedy Show
-
- | Antitrust and Competition Antitrust and Competition
- | Podcast Appearance Podcast Appearance
The Pandemic's Effect on Schools and School Choice | The Chris Spangle Show
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Re: Response to Request for Information (RFI): Commonsense Policy Options to Lower Drug Prices for Patients
-
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Comments on the Section 301 Investigation Regarding Germany’s Persistent Underpayment for Innovative Pharmaceutical Products
Submission to the United States Trade Representative (USTR), Docket Nos. USTR-2026-0463 and USTR-2026-0464 -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Foreign Governments’ Ex Ante DMA-Style Rules Harm Competition and Innovation in Digital Markets While Discriminating Against US Firms
Examines how DMA-style digital regulation affects competition, trade, and antitrust policy -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Consultation on the First Review of the Digital Markets Act
Posted by the European Commission Directorate-General for Competition, Directorate-General for Communications Networks, Content and Technology on July 3, 2025 -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Comments to the UK Intellectual Property Office on the Proposed Regulatory Framework for Establishing a Rate Determination Track (RDT) to Solve Rate Disputes for Standard Essential Patents (SEPs)
Why UKIPO’s plan for IPEC to set SEP royalty rates threatens innovation, IP rights, and UK competitiveness -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
Omnicom Group Inc. (‘‘Omnicom’’) and the Interpublic Group of Companies, Inc. (‘‘IPG’’); Analysis of Agreement Containing Consent Order to Aid Public Comment
Comment urges FTC to clarify that the Order targets only joint, collusive behavior and not unilateral decisions by Omnicom -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
The Federal Trade Commission’s and the U.S. Department of Justice’s Request for Information on Harmful Practices and on Potential Regulation or Legislation to Protect Consumers in the Concert and Entertainment Industry
Comment urges the FTC and DOJ to target specific anticompetitive conduct and adopt consumer-focused rules instead of structural breakups -
- | Antitrust and Competition Antitrust and Competition
- | Public Interest Comments Public Interest Comments
The European Commission's Draft "Proposal for a Regulation of the European Parliament and of the Council on Standard Essential Patents" is Unnecessary and Harmful
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
AI Chatbots Are Helping Youths Improve Their Mental Health | DC Journal
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
The SEARCH Act Copies Europe’s Homework—and Its Mistakes | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Event Video Event Video
Right Diagnosis, Wrong Cure: Examining the True Cost of Drug Price Controls
The Mercatus Center hosted a discussion examining the true cost of drug price controls and the impacts on healthcare affordability, medicinal R&D, and innovation -
- | Antitrust and Competition Antitrust and Competition
- | Feature Feature
Right Diagnosis, Wrong Cure | Regulation
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Fixing Patent Eligibility Is an Easy Win for Innovation | The Daily Economy
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Don’t Put the Government on the Cap Table | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
When rare bipartisanship threatens US tech leadership | Washington Examiner
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Bad Medicine: Why Breaking Up Big Health Care Could Make It Worse | Truth on the Market
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
Getting The Bureaucracy Out of Broadband | The Daily Economy
-
- | Antitrust and Competition Antitrust and Competition
- | Expert Commentary Expert Commentary
California’s latest attack on big tech is BASED on bad economics | Los Angeles Daily News